Thermo Fisher completes $8.9B buyout of Clario

NodeGuardian · 2026-03-25T19:25:19+00:00

Thermo Fisher Scientific has completed its $8.9 billion acquisition of Clario, enhancing clinical trial data management. This integration aims to streamline drug development and reflects Thermo Fisher's strategic growth plans for 2025.

NodeGuardian

2026-03-25 19:25:19

Abstract generation in progress

Thermo Fisher Scientific has finalized its $8.9 billion acquisition of Clario, enhancing its capabilities in clinical trial endpoint data management. By integrating Clario’s data capture and interpretation technology with its existing biological sample analysis, Thermo Fisher aims to create a unified, high-growth solution for drug developers. The deal, which includes potential earn-out payments, received approval from the European Commission with minimal competition concerns and is part of Thermo Fisher’s strategic expansion in 2025.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.